2026: MSc in “Neoplastic Diseases in Humans: Research and Clinicopathological Approach in the Context of Personalised Medicine (Diagnosis and Targeted Therapy),” School of Medicine, National and Kapodistrian University of Athens
2012–2018: Degree in Medicine (MD), School of Medicine, National and Kapodistrian University of Athens
2025: Clinical training in Medical Oncology at Gustave Roussy, Villejuif–Paris, France
2021–2025: Resident in Medical Oncology, Kifissia General Oncology Hospital “Agioi Anargyroi,” Athens, Greece During this period, completed a three-month rotation in the Department of Haematology at “Sismanogleio” General Hospital of Attica and a three-month rotation in the Department of Radiation Oncology at “Agios Savvas” Anticancer Hospital
2019–2021: Resident in Internal Medicine, Department of Internal Medicine, General Hospital of Argolis–Nafplio Hospital Unit, Greece
Baldini C, Seknazi L, Gkolemi N, Goldschmidt V, Ouali K, Sakkal M. Feasibility and clinical relevance of the G-CODE in older adults treated in Phase 1 clinical trials at Gustave Roussy. SSRN. Posted October 15, 2025. doi:10.2139/ssrn.5588571.
Papadakos SP, Stergiou IE, Gkolemi N, Arvanitakis K, Theocharis S. Unraveling the significance of EPH/ephrin signaling in liver cancer: Insights into tumor progression and therapeutic implications. Cancers. 2023;15:3434.
Papadakos SP, Dedes N, Gkolemi N, Machairas N, Theocharis S. The EPH/ephrin system in pancreatic ductal adenocarcinoma (PDAC): From pathogenesis to treatment. International Journal of Molecular Sciences. 2023;24:3015.
A Phase III, Randomised, Open-label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant compared with physician’s choice of Adjuvant Endocrine therapy in patients with Estrogen-Receptor positive, HER2-negative early breast cancer.
A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants with previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy.
A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy (TrilynX).
